Open AccessPrediction of gastric cancer prognosis in the next-generation sequencing era
Author(s) -
Hui Cai,
Xiaomei Hou,
Yibo Ding,
Zhongxing Fu,
Ling Wang,
Yan Du
Publication year - 2019
Publication title -
traditional medicine and modern medicine
Language(s) - English
Resource type - Journals
eISSN - 2575-9019
pISSN - 2575-9000
DOI - 10.1142/s2575900019300029
Subject(s) - exome sequencing , dna sequencing , epigenetics , cancer , computational biology , exome , cancer genome sequencing , biology , targeted therapy , bioinformatics , medicine , gene , genetics , mutation
Gastric cancer (GC) is one of the most commonly diagnosed malignancies worldwide, and is caused by complex interactions of multiple risk factors such as environmental (Helicobacter pylori and Epstein–Barr Virus), hereditary (genetic alterations and epigenetic modifications), as well as dietary and lifestyle factors. GC is usually detected at an advanced stage, with a dismal prognosis. Even for patients with similar clinical or pathologic stage receiving similar treatment, the outcomes are still uneven and unpredictable. To better incorporate genetic and epigenetic profiles into GC prognostic predication, gene expression signatures have been developed to predict GC outcomes. More recently, the advancement of high-throughput sequencing technology, also known as next-generation sequencing (NGS) technology, and analysis has provided the basis for accurate molecular classification of GC tumors. Here, we summarized and updated the literature related to NGS studies of GC, including whole-genome sequencing, whole-exome sequencing, RNA sequencing, and targeted sequencing, and discussed current progresses. NGS has facilitated the identification of genetic/epigenetic targets for screening as well as development of targeted agent therapy, thus enabling individualized patient management and treatment.